← Back to Search

Proton Beam Therapy

Radiation + Androgen Suppression for Prostate Cancer

Phase 3
Recruiting
Led By Carlos Vargas, MD
Research Sponsored by Proton Collaborative Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must be at least 18 years old
Histological evaluation of prostate biopsy with assignment of a Gleason score to the biopsy material; Gleason score must be in the range of 2-7. > 6 cores are strongly recommended
Must not have
Previous prostate cancer surgery to include: prostatectomy, hyperthermia and cryosurgery
Previous pelvic radiation for prostate cancer
Timeline
Screening 3 weeks
Treatment Varies
Follow Up after the initial 100 patients have had a median follow up of at least three years and then every year.
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Summary

This trial will compare the effectiveness of two treatments for prostate cancer.

Who is the study for?
Men with intermediate-risk prostate cancer who have not had previous prostate surgery, androgen suppression therapy, or pelvic radiation. They must be in good physical condition (ECOG 0-1), have a Gleason Score of 7, PSA levels between 10-20 ng/ml, T stage T2b-T2c, and no major medical issues that could affect the study.
What is being tested?
The trial is testing hypofraction proton therapy alone versus proton therapy combined with androgen suppression. Participants will receive either just the radiation treatment or both treatments to see which is more effective at treating localized prostate cancer.
What are the potential side effects?
Potential side effects include skin reactions from radiation like redness or irritation, fatigue due to treatment stress on the body, urinary issues such as increased frequency or discomfort during urination, bowel changes including diarrhea or rectal discomfort.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
My prostate cancer has a Gleason score between 2 and 7, based on more than 6 biopsy samples.
Select...
My breast cancer is in an early stage and has not spread to lymph nodes or other parts of my body.
Select...
My prostate is smaller than 55cc before starting active surveillance.
Select...
My prostate cancer is at intermediate risk of coming back, confirmed by tests within the last year.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had surgery for prostate cancer, including removal, heating, or freezing of the prostate.
Select...
I have had radiation therapy for prostate cancer in the pelvic area.
Select...
I have had hormone therapy for prostate cancer.
Select...
I have had chemotherapy for prostate cancer before.
Select...
I have had a blockage in my urethra that needed stretching.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~after the initial 100 patients have had a median follow up of at least three years and then every year.
This trial's timeline: 3 weeks for screening, Varies for treatment, and after the initial 100 patients have had a median follow up of at least three years and then every year. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Morbidity Outcomes
Secondary study objectives
Frequency and severity of grade 2 or higher GU and GI toxicity

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Radiation + Androgen SuppressionExperimental Treatment2 Interventions
Androgen Suppression Therapy x 6 months + Radiation
Group II: Radiation AloneActive Control1 Intervention
Proton Radiation Total Dose=70 Gy(RBE) OR High Dose Radiation with IMRT Alone=81 Gy OR Intraoperative LDR Brachytherapy and IMRT=45 Gy
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Radiation
2003
Completed Phase 2
~780

Find a Location

Who is running the clinical trial?

Proton Collaborative GroupLead Sponsor
9 Previous Clinical Trials
40,942 Total Patients Enrolled
2 Trials studying Prostate Cancer
72 Patients Enrolled for Prostate Cancer
Carlos Vargas, MDPrincipal InvestigatorProton Collaborative Group
4 Previous Clinical Trials
40,167 Total Patients Enrolled
1 Trials studying Prostate Cancer
2 Patients Enrolled for Prostate Cancer

Media Library

Proton Beam Radiation Therapy (Proton Beam Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT01492972 — Phase 3
Prostate Cancer Research Study Groups: Radiation Alone, Radiation + Androgen Suppression
Prostate Cancer Clinical Trial 2023: Proton Beam Radiation Therapy Highlights & Side Effects. Trial Name: NCT01492972 — Phase 3
Proton Beam Radiation Therapy (Proton Beam Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01492972 — Phase 3
~14 spots leftby Dec 2025